Priapism and renal colic in a patient treated with duloxetine

G. Lucy Wilkening, PharmD¹
Shelly A. Kucherer, MD²
Antoine B. Douaihy, MD³

Abstract
Antidepressant medications are associated with a variety of genitourinary and adverse sexual effects, such as urinary hesitation, priapism, and delayed ejaculation. Here, we report a case of priapism and renal colic following initiation of duloxetine in a patient with history of tolerated selective serotonin reuptake inhibitor treatment. To our knowledge, this represents the first report of priapism and renal colic associated with duloxetine use. This case contributes to the current body of evidence describing adverse genitourinary and sexual effects associated with antidepressant medications.

Keywords: adverse drug reactions, sexual side effects, antidepressants, serotonin-norepinephrine reuptake inhibitor

Background
Sexual side effects, including delayed ejaculation, decreased libido, priapism, and anorgasms, are associated with the use of antidepressant medications and untreated psychiatric illness.¹ While sexual side effects are relatively common, their exact incidence remains unclear as they are hypothesized to be underreported by patients unless asked about them specifically.² The rates of individual sexual side effects among different classes of antidepressants are variable. Studies have shown that duloxetine, a serotonin-norepinephrine reuptake inhibitor, possesses a similar sexual side-effect profile to that of the selective serotonin reuptake inhibitors (SSRIs).³ Specifically, priapism has been associated with the use of citalopram, fluoxetine, paroxetine, and sertraline.⁴⁻⁷ Priapism is defined as an erection that is painful and persists beyond or is unrelated to sexual stimulation; it is thought that roughly 30% of cases are medication induced.¹⁰ Despite similarities in adverse sexual effect profiles, a PubMed literature search using the Medical Subject Heading terms priapism, duloxetine, and antidepressive agents conducted in April 2015 yielded no results reporting priapism associated with duloxetine use. Additionally, priapism is not listed as a potential adverse effect within the duloxetine prescribing information.¹¹

Other genitourinary (GU) side effects, such as erectile dysfunction or urinary hesitancy, are also reported to occur with antidepressant treatment. Renal colic is a severe unilateral flank pain that radiates to the groin and occurs most frequently with the passage of a kidney stone through the ureter or by obstruction of the urinary tract.¹² Although urethral resistance and urinary hesitation have been reported as adverse GU effects of duloxetine,¹¹ a PubMed literature search in April 2015 using the Medical SubjectHeading terms renal colic and antidepressive agents did not yield any results reporting renal colic associated with duloxetine use. However, renal colic is not listed as a potential adverse effect within the duloxetine prescribing information.¹¹

¹ (Corresponding author) Assistant Professor, Department of Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas, wilkenin@uiwtx.edu; Previously: Western Psychiatric Institute and Clinic of the University of Pittsburgh Medical Center; ² PGY-2 Psychiatry Resident, Western Psychiatric Institute and Clinic of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; ³ Medical Director of Addiction Medicine Services, Professor of Psychiatry and Medicine, Western Psychiatric Institute and Clinic of the University of Pittsburgh Medical Center; The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Disclosures: Dr Douaihy has the following disclosures: research grants (NIMH, NIDA, NIAAA, and Orexo) and royalties from Oxford University Press for 2 academic books. Dr Wilkening and Dr Kucherer have no actual or potential conflicts of interest to report in relation to this publication.

© 2016 CPNP. The Mental Health Clinicianis a publication of the College of Psychiatric and Neurologic Pharmacists. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
agents yielded no results. Thus, the following report outlines a case of priapism and renal colic observed after initiation of duloxetine in a patient who previously tolerated treatment with an SSRI. To our knowledge, this represents the first publication reporting this occurrence.

**Case Report**

Mr C is a 39-year-old white man with a past psychiatric history of depressive disorder (not otherwise specified), opioid dependence, and benzodiazepine dependence who was admitted to an inpatient psychiatric facility after a suicide attempt. Psychiatric diagnoses were assigned by the treating psychiatrist according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition criteria. On admission, the urine drug screen was positive for barbiturates (prescribed phenobarbital for maintenance of seizure disorder), benzodiazepines (alprazolam abuse 2 days before admission), opioids (heroin use day before admission), and cocaine (last use the day before admission). He denied history of complicated withdrawal or withdrawal seizures. His past medical history was significant for nephrolithiasis as a young adult (last episode 20 years ago), chronic low back pain, and a baseline seizure disorder secondary to repeated concussions. On admission, Mr C reported taking gabapentin 600 mg orally 4 times daily, phenobarbital 162 mg orally twice a day, escitalopram 20 mg orally daily, and aripiprazole 10 mg orally daily. He reported medication nonadherence to escitalopram and aripiprazole for 4 months before admission.

Mr C was admitted and reinitiated on home medications. Escitalopram and aripiprazole were ordered for treatment of depressive symptoms but initiated at lower doses because of medication nonadherence. For benzodiazepine and heroin dependence, he was initiated on inpatient withdrawal assessment protocols on day 1 of admission and continued for 8 days on diazepam and 7 days on buprenorphine/naloxone, respectively. The patient denied any history of taking alternative antidepressants to treat depression, and he had no evidence of mental illness. He denied history of taking any alternative medications to treat his chronic pain, and he denied any history of taking alternative medications to treat his chronic pain. He denied history of taking any alternative medications to treat his chronic pain, and he denied any history of taking any alternative medications to treat his chronic pain.

On admission, the urine drug screen was positive for barbiturates, phenobarbital, and cocaine. He was noted to have near complete resolution of adverse effect symptoms within 2 days of initiation of duloxetine. Given the rapid improvement in GU symptoms after discontinuation of duloxetine, further workup to rule out nephrolithiasis was not performed. The patient was restarted on escitalopram and had no further complications during his hospitalization.

**Discussion**

Priapism has been previously estimated to have an incidence of 1.5 per 100 000 person years and may arise secondary to several causes. Priapism is thought to occur via 2 distinct mechanisms, specifically, low-flow and high-flow priapism. Low-flow priapism is related to trauma or is idiopathic. Low-low priapism has more diverse causes and is often due to medications, sickle cell disease, or leukemia, or it may also be idiopathic. Duloxetine’s mechanism of action involves inhibition of neuronal serotonin and norepinephrine reuptake without significant affinity for histaminergic, cholinergic, or adrenergic receptors. Previous reports of SSRI-induced priapism have hypothesized serotoninergic mechanisms involving specific serotonin receptors, while reviews of other psychotropic mechanisms, such as trazadone and certain neuroleptics, have suggested the role of alpha-adrenergic blockade resulting in priapism. In terms of serotonin receptor involvement, it has been shown that a penile erection is caused by 5-hydroxytryptamine (5-HT)1B and 5-HT3 receptor stimulation, while 5-HT3 or 5-HT2 receptor stimulation inhibits penile erection. Previous reports have implicated cocaine abuse as a cause of priapism through its effect on norepinephrine reuptake and persistent systemic vasoconstriction. A case report of the serotonin-norepinephrine reuptake inhibitor venlafax-
ine, associated with priapism in a young man with history of alcohol and cannabis abuse, has also been published. When postulating a mechanism for duloxetine-induced priapism, involvement of serotonin, norepinephrine, or a combination of the two is plausible. Given our patient’s history of SSRI tolerance, it stands to reason that noradrenergic activity may have been involved in our patient. Trials aimed specifically at evaluating the sexual side-effect profile of duloxetine found that men treated with duloxetine had a significant increase in difficulty reaching orgasm compared with those treated with placebo. In contrast, priapism was not reported.

Renal colic is characterized as acute radiating flank pain associated with obstruction of the ureter, and it is often accompanied with hematuria, dysuria, nausea, and vomiting. Previous studies have found that more than 1 million patients visiting the emergency department each year are diagnosed with renal colic or renal calculus. To our knowledge, no case reports exist describing the occurrence of renal colic associated with antidepressant agents, and the exact mechanism by which such an adverse effect might occur is unclear. However, a plausible explanation may exist when considering duloxetine’s role in the treatment of stress urinary incontinence. Studies have shown that duloxetine’s inhibitory effects on the presynaptic reuptake of serotonin and norepinephrine result in increased contractility of the urethral sphincter, the musculature that regulates the flow of urine from the bladder. Further, duloxetine has been approved in Europe as a treatment for stress urinary incontinence in females for over a decade.

Our case presents novel information regarding potential GU and adverse sexual effects of duloxetine. However, several limitations should be discussed, primarily, the patient’s history of nephrolithiasis as a young adult. Although nephrolithiasis cannot be completely ruled out by the workup presented, other symptoms consistent with nephrolithiasis and renal colic, such as polyuria, nausea, vomiting, fever, and ileus were not present in our patient. Additionally, the patient noted that his previous courses of nephrolithiasis persisted for longer durations of time compared with this episode. Nevertheless, nephrolithiasis should be considered as a potential alternative cause of renal colic in this report. Second, cocaine use may confound the identifiable etiology of priapism in some patient presentations, as this phenomenon has been reported previously. However, given the time of our patient’s last use of cocaine to the time of priapism (1 week), the authors concluded that this mechanism was unlikely. Lastly, the development of adverse effects after a single, initial dose of duloxetine also warrants discussion. Certain adverse sexual effects associated with antidepressants, such as anorgasmia and delayed ejaculation, are thought to be dose- and accumulation-related phenomena. Conversely, priapism appears to be a potential risk at any time during treatment with psychotropics, with a timeline ranging from initiation of treatment up to 2 years after initiation being reported in the literature. Therefore, the priapism experienced by our patient falls within the range of timelines previously reported.

Both adverse events experienced by our patient were rated individually using the Naranjo adverse drug reaction likelihood scoring system. Priapism was graded as a Naranjo score 6 (probable) based on answers to each of the following questions: did the adverse event appear after suspected drug was given (yes, 2 points); did the adverse reaction improve when the drug was discontinued (yes, 1 point); could alternative causes have produced the reaction (no, 2 points); was the event confirmed by objective evidence (yes–physical exam findings, 1 point). Renal colic was scored as a 3 (possible) by answers to the following: did the adverse event appear after suspected drug was given (yes, 2 points); did the adverse reaction improve when the drug was discontinued (yes, 1 point); could alternative causes have produced the reaction (yes, 1 point); was the adverse event confirmed by objective evidence (yes, 1 point). These adverse events were reported to the US Food and Drug Administration Event Reporting System as well as the adverse event review board at our institution.

**Conclusion**

Patients who tolerate treatment with SSRIs, such as escitalopram, may still be at risk for adverse GU and sexual side effects associated with duloxetine treatment.

**References**

1. Clayton AH, El Haddad S, Iluonakhamhe JP, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf. 2014;13(10):1361-74. DOI: 10.1517/14740338.2014.952324. PubMed PMID: 25148932.
2. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002;36(10):1577-89. PubMed PMID: 12243609.
3. Dueñas H, Brnabic AJM, Lee A, Montejo AL, Prakash S, Casimiro-Querubin MLS, et al. Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period. Int J Psychiatry Clin Pract. 2011;15(4):242-54. DOI: 10.3109/13651501.2011.590209. PubMed PMID: 22121997.
4. Ahmad S. Paroxetine induced priapism. Arch Intern Med. 1995;155(6):645. PubMed PMID: 7887764.
5. Bonnot O, Warot D, Cohen D. Priapism associated with sertraline. J Am Acad Child Adolesc Psychiatry. 2007;46(7):790-1. DOI: 10.1097/chi.0b013e318067da56. PubMed PMID: 17582142.
6. Javed MA. Priapism associated with fluoxetine therapy: a case report. J Pak Med Assoc. 1996;46(2):45-6. PubMed PMID: 8683851.
7. Dent LA, Brown WC, Murney JD. Citalopram-induced priapism. Pharmacotherapy. 2002;22(4):538-41. PubMed PMID: 11939691.
8. Harmon WJ, Nehra A. Priapism: diagnosis and management. Mayo Clin Proc. 1997;72(4):350-5. DOI: 10.4065/72.4.350. PubMed PMID: 9121183.
9. Berger RK, Billups G, Brock GA, Broderick CB, Dhabuwala I, Goldstein LS, et al. Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism. Int J Impot Res. 2001;13 Suppl 5:S39-43. PubMed PMID: 11781746.
10. Baños JE, Bosch F, Farre M. Drug-induced priapism. Its aetiology, incidence and treatment. Med Toxicol Adverse Drug Exp. 1989; 4(1):46-58. PubMed PMID:2651850.
11. Cymbalta (duloxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; November 2014.
12. Haddad MC, Sharif HS, Shahed MS, Mutaiery MA, Sammak BM, et al. Renal colic: diagnosis and outcome. Radiology. 1992;184(1):83-8. DOI: 10.1148/radiology.184.1.1609107. PubMed PMID: 1609107.
13. Elaid A, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology. 2001;57(5):970-2. PubMed PMID: 11337305.
14. Dent LA, Brown WC, Murney JD. Citalopram-induced priapism. Pharmacotherapy. 2002;22(4):538-41. DOI: 10.1592/phco.22.7.538.ss0072. PubMed PMID: 11939691.
15. Thompson JW, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry. 1990; 51(10):430-3. PubMed PMID: 22115462.
16. Dubin NN, Razack AH. Priapism: ecstasy related? Urology. 2000; 55(6):1057. DOI: 10.1016/S0090-4295(00)00839-6. PubMed PMID: 11113767.
17. Altman AL, Seftel AD, Brown SL, Hampel N. Cocaine associated priapism. J Urol. 1993;161(6):1817-8. PubMed PMID: 10332443.
18. Samuel RZ. Priapism associated with venlafaxine use. J Am Acad Child Adolesc Psychiatry. 2000;39(1):16-7. DOI: 10.1097/00004583-200001000-00010. PubMed PMID: 10638063.
19. Brown J. Diagnostic and treatment patterns for renal colic in US emergency departments. Int Urol Nephrol. 2006;38(1):87-92. DOI: 10.1007/s11255-005-3622-6. PubMed PMID: 16502058.
20. Schlenker B, Gratze K, Reich O, Schorsch I, Seitz M, Stief CG. Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy. Eur Urol. 2006;49(6):1075-8. DOI: 10.1016/j.eururo.2006.01.038. PubMed PMID: 16481094.
21. Neff D, Guise A, Guralnick ML, Langenstroer P, See WA, Jacobsohn KM, O’Connor RC. Duloxetine for the treatment of post-prostatectomy stress urinary incontinence. Can Urol Assoc J. 2013;7(5-6):E260-2. DOI: doi: 10.5489/cuaj.318. PubMed PMID: 23766216.
22. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1): 67-85. PubMed PMID: 9934946.
23. Paklet L, Abe AM, Olajide D. Priapism associated with risperidone: a case report, literature review and review of the South London and Maudsley hospital patients’ database. Ther Adv Psychopharmacol. 2013;3(1):3-13. DOI: 10.1177/2045253212464104. PubMed PMID: 23983987.
24. Naranjo CA, Bustu U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. PubMed PMID: 7249508.